The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry
Open accessAbstract
BACKGROUND: Limited data are available on the characteristics, clinical management, and outcomes of patients with atrial fibrillation at risk of stroke, from a worldwide perspective. The aim of this study was to describe the baseline characteristics and initial therapeutic management of patients with non-valvular atrial fibrillation across the spectrum of sites at which these patients are treated. METHODS AND FINDINGS: The Global Anticoagulant Registry in the FIELD (GARFIELD) is an observational study of patients newly diagnosed with non-valvular atrial fibrillation. Enrollment into Cohort 1 (of 5) took place between December 2009 and October 2011 at 540 sites in 19 countries in Europe, Asia-Pacific, Central/South America, and Canada. Investigator sites are representative of the distribution of atrial fibrillation care settings in each country. Cohort 1 comprised 10,614 adults (≥18 years) diagnosed with non-valvular atrial fibrillation within the previous 6 weeks, with ≥1 investigator-defined stroke risk factor (not limited to those in existing risk-stratification schemes), and regardless of therapy. Data collected at baseline included demographics, medical history, care setting, nature of atrial fibrillation, and treatments initiated at diagnosis. The mean (SD) age of the population was 70.2 (11.2) years; 43.2% were women. Mean±SD CHADS2 score was 1.9±1.2, and 57.2% had a score ≥2. Mean CHA2DS2-VASc score was 3.2±1.6, and 8,957 (84.4%) had a score ≥2. Overall, 38.0% of patients with a CHADS2 score ≥2 did not receive anticoagulant therapy, whereas 42.5% of those at low risk (score 0) received anticoagulant therapy. CONCLUSIONS: These contemporary observational worldwide data on non-valvular atrial fibrillation, collected at the end of the vitamin K antagonist-only era, indicate that these drugs are frequently not being used according to stroke risk scores and guidelines, with overuse in patients at low risk and underuse in those at high risk of stroke. TRIAL REGISTRATION: ClinicalTrials.gov TRI08888.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Self-citationApixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,115
Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010) · Chest · doi:10.1378/chest.09-1584 · Cited by 6,879
Self-citationDeveloped with the special contribution of the European Heart Rhythm Association (EHRA), Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), Authors/Task Force Members, Camm, A. J., Kirchhof, P., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Van Gelder, I. C., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq278 · Cited by 5,864
Self-citationGage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,822
Self-citationApixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483 · cited 1×
“Despite mandating the presence of one or more additional stroke risk factors in an effort to exclude patients with lone AF, the GARFIELD population fares as relatively low risk compared with other observational cohorts, and is substantially lower risk than the populations included in randomized trials of novel oral an…”
Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., & Palareti, G. (2008) · Chest · doi:10.1378/chest.08-0670 · Cited by 2,118
Wann, L. S., Curtis, A. B., January, C. T., Ellenbogen, K. A., Lowe, J. E., Estes, N. A. M., Page, R. L., Ezekowitz, M. D., Slotwiner, D. J., Jackman, W. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3181fa3cf4 · Cited by 1,336
Systematic overview of warfarin and its drug and food interactions
Holbrook, A. M. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.10.1095 · Cited by 1,160 · cited 1×
“VKAs have a number of drawbacks, however, including a narrow therapeutic window, multiple food and drug interactions [8], and substantial inter-patient variability due to genetic or other factors, making their long-term use in clinical practice a challenge [9].”
BackgroundFuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Kay, G. N., Le Huezey, J.-Y., Lowe, J. E., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.013 · Cited by 924
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Kay, G. N., Le Huezey, J.-Y., Lowe, J. E., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318214876d · Cited by 859
Atrial fibrillation management: a prospective survey in ESC Member Countries
Nieuwlaat, R., Capucci, A., Camm, A. J., Olsson, S. B., Andresen, D., Davies, D. W., Cobbe, S., Breithardt, G., Le Heuzey, J.-Y., Prins, M. H., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi505 · Cited by 829
Authors/Task Force Members, Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl176 · Cited by 644
Olesen, J., Torp-Pedersen, C., Hansen, M., & Lip, G. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-03-0175 · Cited by 485
Self-citationKirchhof, P., Auricchio, A., Bax, J., Crijns, H., Camm, J., Diener, H.-C., Goette, A., Hindricks, G., Hohnloser, S., Kappenberger, L., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm358 · Cited by 380
Self-citationNieuwlaat, R., Capucci, A., Lip, G. Y. H., Olsson, S. B., Prins, M. H., Nieman, F. H., Lopez-Sendon, J., Vardas, P. E., Aliot, E., Santini, M., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl015 · Cited by 369
Self-citationSTEGER, C., PRATTER, A., MARTINEKBREGEL, M., AVANZINI, M., VALENTIN, A., SLANY, J., & STOLLBERGER, C. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.06.030 · Cited by 303
Cairns, J. A., Connolly, S., McMurtry, S., Stephenson, M., & Talajic, M. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2010.11.007 · Cited by 292
Nieuwlaat, R., Prins, M. H., Le Heuzey, J.-Y., Vardas, P. E., Aliot, E., Santini, M., Cobbe, S. M., Widdershoven, J. W. M. G., Baur, L. H., Levy, S., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn139 · Cited by 287
The Global Registry of Acute Coronary Events, 1999 to 2009–GRACE
Fox, K. A. A., Eagle, K. A., Gore, J. M., Steg, P. G., Anderson, F. A., & for the GRACE and GRACE2 Investigators (2010) · Heart · doi:10.1136/hrt.2009.190827 · Cited by 272
Self-citationGoto, S., Bhatt, D. L., Röther, J., Alberts, M., Hill, M. D., Ikeda, Y., Uchiyama, S., D'Agostino, R., Ohman, E. M., Liau, C.-S., et al. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.06.029 · Cited by 259
Self-citationKakkar, A. K., Mueller, I., Bassand, J.-P., Fitzmaurice, D. A., Goldhaber, S. Z., Goto, S., Haas, S., Hacke, W., Lip, G. Y. H., Mantovani, L. G., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2011.09.011 · Cited by 234
Self-citationSteg, P. G., Alam, S., Chiang, C., Gamra, H., Goethals, M., Inoue, H., Krapf, L., Lewalter, T., Merioua, I., Murín, J., et al. (2011) · Heart · doi:10.1136/heartjnl-2011-300550 · Cited by 164
Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk?
ZIMETBAUM, P. J., Thosani, A. J., Yu, H.-T., Xiong, Y., Lin, J., Kothawala, P., & Emons, M. F. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.11.015 · Cited by 155
Racial Differences in the Prevalence of Atrial Fibrillation among Males
Borzecki, A. M., McInnes, D. K., Liebschutz, J. M., Kader, B., Kazis, L. E., & Berlowitz, D. R. (2008) · Journal of the National Medical Association · doi:10.1016/s0027-9684(15)31212-8 · Cited by 134
Trends in the prevalence, awareness, treatment and control of hypertension: the WHO MONICA Project
Antikainen, R. L., Moltchanov, V. A., Chukwuma, C., Kuulasmaa, K. A., Marques-Vidal, P. M., Sans, S., Wilhelmsen, L., & Tuomilehto, J. O. (2006) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/00149831-200602000-00004 · Cited by 132
Tulner, L. R., van Campen, J. P. C. M., Kuper, I. M. J. A., Gijsen, G. J. P. T., Koks, C. H. W., Gillavry, M. R. M., van Tinteren, H., Beijnen, J. H., & Brandjes, D. P. M. (2009) · Drugs & Aging · doi:10.2165/11319540-000000000-00000 · Cited by 111
Cited by
Global epidemiology of atrial fibrillation
Rahman, F., Kwan, G. F., & Benjamin, E. J. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.118 · Cited by 731
Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study
Svennberg, E., Engdahl, J., Al-Khalili, F., Friberg, L., Frykman, V., & Rosenqvist, M. (2015) · Circulation · doi:10.1161/circulationaha.114.014343 · Cited by 605
Andrade, J. G., Aguilar, M., Atzema, C., Bell, A., Cairns, J. A., Cheung, C. C., Cox, J. L., Dorian, P., Gladstone, D. J., Healey, J. S., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.09.001 · Cited by 562
Stroke prevention in atrial fibrillation
Freedman, B., Potpara, T. S., & Lip, G. Y. H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31257-0 · Cited by 463
Self-citationKirchhof, P., Ammentorp, B., Darius, H., De Caterina, R., Le Heuzey, J.-Y., Schilling, R. J., Schmitt, J., & Zamorano, J. L. (2014) · EP Europace · doi:10.1093/europace/eut263 · Cited by 404
Metadata
- Authors
- Kakkar, A. K., Mueller, I., Bassand, J.-P., Fitzmaurice, D. A., Goldhaber, S. Z., Goto, S., Haas, S., Hacke, W., Lip, G. Y. H., Mantovani, L. G., Turpie, A. G. G., van Eickels, M., Misselwitz, F., Rushton-Smith, S., Kayani, G., Wilkinson, P., Verheugt, F. W. A., & for the GARFIELD Registry Investigators
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-05-21
- Volume
- 8
- Issue
- 5
- Pages
- e63479
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2141347595
- Cited by
- 444
- References
- 30
- FWCI
- 35.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.